Technology Offers to remove

 – Elisa for diagnosis of infections with Chlamydia suis

Chlamydia suis-specific antibody ELISA (indirect) with high specificity and sensitivity

Our Chlamydia suis-specific ELISA has the following advantages:

  • easily applicable for routine analysis
  • acceptable cost for swine producers
  • can be used to support the production of Chlamydia suis sero-negative pigs/breeding stock
  • can be used to prevent venereal transmission by serological monitoring of boars on the farms and in artificial insemination centers
  • can be used on human samples
  • can detect persistent asymptomatic Chlamydia suis infections

– Safe and effective Salmonella vaccines for poultry

Attenuated vaccines based on Salmonella deletion mutant strains (with defective multi drug resistance (MDR) efflux pump systems)

– COLIGO, a novel alternative to antibiotics to protect piglets against diarrhoea

COLIGO interferes with the attachment of F18+ E coli to the pig’s intestinal epithelium.  In vivo results demonstrate it significantly reduces duration of shedding and the quantity of F18+ E coli bacteria that are colonising the intestine and being shed in the environment.

– Permissive cells for PRRSV production – LICENSED

The PRRS-virus can infect the cells via the natural route due to the presence of both sialoadhesin and CD163, the two receptors that are essential for binding, internalization and multiplication

– Effective and safe inactivated viral vaccines – LICENSED

Our technology enables you to check the antigenicity (efficacy) and safety of your inactivated viral vaccine in vitro

– PCV2: identification of different strains

We describe monoclonal antibodies that can be used to identify antigenic differences between PCV2 strains

– Ostertagia ostertagi antibody ELISA – LICENSED

Ostertagia ostertagi is one of the most important gastrointestinal nematodes for cattle worldwide. As Ostertagia ostertagi is present on pasture, all grazing cattle in temperate climate regions are exposed to the parasite

– Fasciola hepatica ELISA – LICENSED

PROVAXS-Ghent University has concluded a partnership agreement with the Swedish veterinary diagnostic company, Boehringer Ingelheim Svanova for the commercial launch of a new ELISA kit. The ELISA was developed at the Laboratory of Parasitology of Professor Jozef Vercruysse at Ghent University

– The SERASCA®- test (Ascaris suum) – LICENSED

At the Laboratory of Parasitology we we have developed an ELISA test that enables us to measure the exposure of pigs to Ascaris suum. The relevance of such a test for pig production is described in the attached document

– Entry portal trough the intestinal barrier

Our technology enables controlled transfer of biological compounds through the intestinal (mucosal) barrier

– CD169, a unique macrophage entry portal for targeted delivery of antigens

A new technology for the induction of high affinity isotype switched antibodies and long lasting antigen presentation based on CD169-targeting

– The first vaccine for Psittaciformes against Cp psittaci 

We have developed a codon-optimized, MOMP-based DNA vaccine that significantly protects birds (Psittaciformes) against a high challenge with the zoonotic pathogen Chlamydophila psittaci (Cp psittaci)

– Safe and effective vaccine against Clostridium perfringens in poultry

The vaccine consists of a combination of NetB and alpha-toxin, both detoxified

– Safe Salmonella DIVA-vaccine 

We developed Salmonella Typhimurium strains of which the humoral response elicited in pigs can easily be differentiated from the humoral response, elicited by a wildtype fieldstrain.

– Thermostable microparticles for antigen/adjuvant delivery

Modular poly-electrolyte microparticle system for multi-component encapsulation including antigens and molecular adjuvants

– Passive immunization (oral) with plant produced antibodies

As a proof of concept we have developed antibodies against F4 fimbriae of Escherichia coli in seeds of Arabidopsis